Experiences of healthcare providers and patients with diabetes mellitus regarding continuous glucose monitoring use in South Korea: a multicenter, cross-sectional survey study
10.12701/jyms.2025.42.60
- Author:
Young-Jin CHOI
;
Jung-Hwa LEE
;
Kyu-Jeung AHN
;
Ho-Yeon CHUNG
;
Ji Eun JUN
;
You-Cheol HWANG
;
Hyuk-Sang KWON
;
Young NA
;
Jae-Hyeon KIM
;
Kang-Hee SIM
;
Kun-Ho YOON
;
Bok-Rye SONG
;
In-Kyung JEONG
- Publication Type:Original article
- From:
Journal of Yeungnam Medical Science
2025;42(1):60-
- CountryRepublic of Korea
- Language:0
-
Abstract:
Background:Despite the increasing use of continuous glucose monitoring (CGM) systems, limited data exist on their perceived benefits and challenges among patients and healthcare providers. This study explored CGM-related experiences in South Korea.
Methods:An anonymous online survey was conducted between January and December 2021 at four university hospitals. Respondents included patients with diabetes mellitus (DM), physicians, and DM education nurses. The survey assessed the use of CGM, its benefits, and barriers. Most devices were first-generation CGMs: FreeStyle Libre 1 (Abbott Diabetes Care), Dexcom G6 (Dexcom Inc.), and Medtronic Guardian 3 (Medtronic MiniMed).
Results:Among 1,010 patients (33.4% with type 1 DM [T1DM], 63.6% with type 2 DM [T2DM], and 3.1% others; mean age, 51.4±14.6 years), 92.7% found CGM helpful. Although 59.6% reported discomfort, 81.9% intended to continue using CGM, indicating that perceived benefits outweighed barriers. The key advantages were glucose monitoring without finger pricks (T1DM, 57.9%; T2DM, 56.2%) and maintenance of target glucose levels. Discomfort was related to discomfort during activities (53.8%), skin problems (45.0%), and pain (43.0%). Healthcare provider recommendations were associated with reduced discomfort (adjusted odds ratio, 0.36; 95% confidence interval, 0.21–0.60). Physicians (n=29) cited high costs as the main barrier (T1DM, 58.9%; T2DM, 64.8%); only 51.9% and 14.5% prescribed CGM for T1DM and T2DM, respectively. Insulin adjustment and glucose control were the main reasons for prescription, while cost (89.3%) and limited consultation time (67.9%) were barriers. DM educators (n=9) reported heavy workloads, with training and follow-up times averaging 31.7±7.5 minutes and 21.7±9.7 minutes, respectively; 77.8% of DM educators identified frequent patient inquiries as their greatest burden.
Conclusion:CGM provides significant clinical benefits but is limited by discomfort, costs, and educational burden. Sustained adoption requires device improvements, insurance support, and workforce expansion.
